Literature DB >> 8831305

Aprotinin reduces interleukin-8 production and lung neutrophil accumulation after cardiopulmonary bypass.

G E Hill1, R Pohorecki, A Alonso, S I Rennard, R A Robbins.   

Abstract

Pulmonary neutrophil entrapment and resultant oxidative injury is thought to be the primary mechanism of cardiopulmonary bypass (CPB) induced lung injury. Interleukin-8 (IL-8), a potent neutrophil chemoattractant induced by cytokines, including tumor necrosis factor-alpha (TNF), is found in increased concentrations in bronchial alveolar lavage fluid (BALF) in lung inflammation. Since aprotinin reduces TNF release during CPB, the effects of aprotinin on BALF IL-8 concentrations and neutrophil levels were determined after CPB in adult humans. Study patients were equally divided into a control group (n = 8, Group 1) and an aprotin-intreated group (n = 8, Group 2). In vitro neutrophil chemotaxis was done with volunteer neutrophils using three different chemoattractants: 1) N-formyl-1-methionyl-1-leucyl-1-phenylalanine (FMLP); 2) the supernatant of a human bronchial epithelial cell culture line, A549, after 24 h of TNF stimulation with or without aprotinin or N-alpha-tosyl-L-lysine chloromethyl ketone (TLCK) (a potent protease inhibitor), and 3) BALF. Aprotinin treatment significantly (P < 0.05) reduced post-CPB BALF IL-8 concentrations and percentage of neutrophils. In vitro, BALF from Group 1 had significantly greater chemotactic ability when compared with Group 2. The TNF stimulated A549 cell culture supernatant had significantly (P < 0.05) greater chemotactic ability than control supernatant, while aprotinin and TLCK significantly (P < 0.05) reduced this chemotactic ability. These results demonstrate that aprotinin blunts IL-8 production and reduces neutrophil lung accumulation post-CPB.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8831305     DOI: 10.1097/00000539-199610000-00006

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  8 in total

1.  Evaluation of biocompatible cardiopulmonary bypass circuit use during pediatric open heart surgery.

Authors:  Joseph Deptula; Kimberly Glogowski; Kellie Merrigan; Kim Hanson; Donald Felix; James Hammel; Kim Duncan
Journal:  J Extra Corpor Technol       Date:  2006-03

Review 2.  Aprotinin: an update of its pharmacology and therapeutic use in open heart surgery and coronary artery bypass surgery.

Authors:  D C Peters; S Noble
Journal:  Drugs       Date:  1999-02       Impact factor: 9.546

3.  Protective effect of silymarin during coronary artery bypass grafting surgery.

Authors:  Tagreed Altaei
Journal:  Exp Clin Cardiol       Date:  2012

4.  Aprotinin modifies left ventricular contractility and cytokine release after ischemia-reperfusion in a dose-dependent manner in a murine model.

Authors:  Matthew D McEvoy; Michel J Sabbagh; Anna Greta Taylor; Juozas A Zavadzkas; Christine N Koval; Robert E Stroud; Rachael L Ford; Julie E McLean; Scott T Reeves; Rupak Mukherjee; Francis G Spinale
Journal:  Anesth Analg       Date:  2009-02       Impact factor: 5.108

5.  Proangiogenic microtemplated fibrin scaffolds containing aprotinin promote improved wound healing responses.

Authors:  Kassandra S Thomson; Sarah K Dupras; Charles E Murry; Marta Scatena; Michael Regnier
Journal:  Angiogenesis       Date:  2013-10-15       Impact factor: 9.596

6.  Aprotinin attenuates the elevation of pulmonary vascular resistance after cardiopulmonary bypass.

Authors:  Tae-Jin Yun; Joon-Ryang Rho
Journal:  J Korean Med Sci       Date:  2006-02       Impact factor: 2.153

Review 7.  Strategies to prevent intraoperative lung injury during cardiopulmonary bypass.

Authors:  Efstratios E Apostolakis; Efstratios N Koletsis; Nikolaos G Baikoussis; Stavros N Siminelakis; Georgios S Papadopoulos
Journal:  J Cardiothorac Surg       Date:  2010-01-11       Impact factor: 1.637

Review 8.  Pulmonary Protection Strategies in Cardiac Surgery: Are We Making Any Progress?

Authors:  Emad Al Jaaly; Mustafa Zakkar; Francesca Fiorentino; Gianni D Angelini
Journal:  Oxid Med Cell Longev       Date:  2015-10-20       Impact factor: 6.543

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.